Alnylam Pharmaceuticals, Inc. ALNY
$205.52
+0.02%
at last close
Financials (TTM)
- Revenue
- $4.80 billion
- Net Income
- $733.11 million
- Net Margin
- 15.26%
- Return on Equity
- 54.14%
- Debt-to-Equity
- —
- P/E Ratio
- 38.27
- Price / Book
- 20.31
- Price / Sales
- 5.72
Over the trailing twelve months, Alnylam Pharmaceuticals, Inc. generated revenue of $4.80 billion and net income of $733.11 million, a net margin of 15.26%.
At the last closing price of $205.52, ALNY trades at 38.27 times trailing earnings and 5.72 times sales, with a market capitalization of $27.50 billion.
Key Stats
- Last Close
- $205.52
- Market Cap
- $27.50 billion
- 52-Week Range
- $197.81 – $495.55
- Average Volume
- 1.89 million shs
Data is delayed and provided for informational purposes only. Not investment advice. See our disclaimer.